Zealand CEO on new milestone: It's a validation of the company
Danish Zealand Pharma can look forward to a three-digit million milestone payment after German partner Boehringer Ingelheim takes one of the drugs in-licensed from Zealand to next development phase. The Danish biotech firm now awaits Boehringer's decision regarding second candidate in the license agreement.
The share price boomed for Danish Zealand Pharma this week after German partner Boehringer Ingelheim announced that it plans to initiate phase II trials with the candidate BI 456906, which was in-licensed from Zealand.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
